Target intelligence / Profile preview

Microbiota homeostasis

01

Overview

Microbiota homeostasis refers to the stable, mutually beneficial relationship between host and resident microbial communities, essential for maintaining health. In humans and animals, this state enables efficient nutrient metabolism, strong mucosal barriers, balanced immune responses, and protection against pathogens[3][4][1][5]. Disruption of this homeostasis—termed dysbiosis—is associated with numerous diseases, including infections, autoimmune disorders, metabolic diseases, and inflammatory conditions[4][5][2][1]. Restoration of microbiota homeostasis using interventions such as probiotics, prebiotics, or fecal microbiota transplantation is a rapidly expanding therapeutic frontier, but it targets an ecosystem state, not a singular molecular entity[2][5][3][4]. Key point: "Microbiota homeostasis" is a *physiological/ecological state*, not a molecular target, receptor, enzyme, or gene product[1][5][4][2]. It cannot be directly mapped to standard druggable targets for traditional pharmacological profiling.

Other names
eubiosismicrobial homeostasismicrobiome balancecommunity equilibrium
02

Mechanism of action

Restoration or modulation of microbial community balance. Suppression of pathogenic overgrowth. Promotion of beneficial microbial species. Immune system modulation via microbial products/metabolites. Enhancement of epithelial barrier function.

03

Biological functions

Immune modulationNutrient metabolismBarrier integrity maintenanceRegulation of inflammationHost-pathogen protectionHormone regulationNeural function modulation (gut-brain axis)
04

Disease associations

InflammationMetabolic diseaseInfection (e.g., Clostridioides difficile infection)Autoimmune diseasesNeurodevelopmental disordersCancer (associated through dysbiosis effects)Other
05

Safety considerations

Infection risk (e.g., from fecal microbiota transplantation)Transfer of antibiotic resistance genesOff-target immune effectsUnknown long-term consequences of major compositional shifts
06

Interacting drugs

Probiotics

5 more in the full profile.

07

Biomarkers

Microbial diversity indicesSpecific taxa abundance (e.g., Firmicutes:Bacteroidetes ratio)Fecal short-chain fatty acidsInflammatory markers (e.g., fecal calprotectin)Secretory IgA levels

Beyond the preview

Go deeper on Microbiota homeostasis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbiota homeostasis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call